

# Phaeochromocytoma

Jacques W M Lenders, Graeme Eisenhofer, Massimo Mannelli, Karel Pacak

Phaeochromocytomas are rare neuroendocrine tumours with a highly variable clinical presentation but most commonly presenting with episodes of headaches, sweating, palpitations, and hypertension. The serious and potentially lethal cardiovascular complications of these tumours are due to the potent effects of secreted catecholamines. Biochemical testing for phaeochromocytoma is indicated not only in symptomatic patients, but also in patients with adrenal incidentalomas or identified genetic predispositions (eg, multiple endocrine neoplasia type 2, von Hippel-Lindau syndrome, neurofibromatosis type 1, and mutations of the succinate dehydrogenase genes). Imaging techniques such as CT or MRI and functional ligands such as  $^{123}\text{I}$ -MIBG are used to localise biochemically proven tumours. After the use of appropriate preoperative treatment to block the effects of secreted catecholamines, laparoscopic tumour removal is the preferred procedure. If removal of phaeochromocytoma is timely, prognosis is excellent. However, prognosis is poor in patients with metastases, which especially occur in patients with large, extra-adrenal tumours.

Phaeochromocytomas are catecholamine-producing neuroendocrine tumours arising from chromaffin cells of the adrenal medulla or extra-adrenal paraganglia. Tumours from extra-adrenal chromaffin tissue are referred to as extra-adrenal phaeochromocytomas or paragangliomas. The term paraganglioma is also used for tumours derived from parasympathetic tissue in the head and neck, most of which do not produce catecholamines. Nearly 80–85% of phaeochromocytomas arise from the adrenal medulla, whereas about 15–20% are from extra-adrenal chromaffin tissue.<sup>1,2</sup> Catecholamine-producing extra-adrenal paragangliomas are usually found in the abdomen.<sup>3,4</sup>

In general outpatient clinics, the prevalence of phaeochromocytoma in patients with hypertension is 0.1–0.6%.<sup>5–7</sup> Although these tumours are frequently searched for, they are rarely found. The relatively high prevalence of phaeochromocytoma in autopsy studies (about 0.05%) also indicates that many tumours are missed, resulting in premature mortality.<sup>8–11</sup>

Hereditary phaeochromocytomas occur in multiple endocrine neoplasia type 2, von Hippel-Lindau syndrome, neurofibromatosis type 1, and the familial paragangliomas.<sup>12–14</sup> Sporadic forms of phaeochromocytoma are usually diagnosed in individuals aged 40–50 years, whereas hereditary forms are diagnosed earlier, most often before age 40 years.<sup>15–17</sup> Phaeochromocytoma is rare in children, but when found it is often extra-adrenal, multifocal, and associated with hereditary syndromes.<sup>1,18,19</sup>

Clinical presentation of phaeochromocytoma can vary greatly, with similar signs and symptoms produced by many other clinical conditions (panel 1). Phaeochromocytoma is therefore often referred to as the great mimic. Most but not all the clinical signs and symptoms of phaeochromocytoma are due to the direct actions of secreted catecholamines. Hypertension, tachycardia, pallor, headache, and feelings of panic or anxiety, usually dominate the clinical presentation (table 1).<sup>17,20,21</sup> Metabolic effects include hyperglycaemia, lactic acidosis, and weight loss.<sup>22</sup> Less common signs and

symptoms are nausea, fever, and flushing. Hypertension is often paroxysmal in nature, in some patients occurring on a background of sustained hypertension, whereas others can have normal blood pressure between paroxysms. Hypertensive episodes can be severe and result in hypertensive emergencies. Blood pressure can also be consistently normal, especially in patients with adrenal incidentalomas, in those screened for an identified familial syndrome, or in those with a very small tumour.<sup>23</sup> Because of increasing use of advanced imaging techniques and improved recognition of genetic causes of phaeochromocytoma, where routine screening is becoming mandatory, the numbers of normotensive and asymptomatic patients diagnosed with the disease have steadily risen.<sup>23–26</sup> About 5% of all incidentalomas are phaeochromocytomas, with about 25% of all phaeochromocytomas now being discovered incidentally during imaging studies for unrelated disorders.<sup>23,26,27</sup>

Normal blood pressure or even hypotension is also common in patients with dopamine-producing paragangliomas, in whom diagnosis is often based on the space-occupying complications of tumours.<sup>28,29</sup> Presumably as a consequence of their asymptomatic nature, these tumours tend to be large; most present with metastases.

Some patients also present with unexplained orthostatic hypotension that, on a background of hypertension, provides an important diagnostic clue for the presence of a phaeochromocytoma. Occasionally,

*Lancet* 2005; 366: 665–675

Department of Internal Medicine, Division of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen 6525GA, Netherlands (Prof W M Lenders MD); Department of Clinical Pathophysiology, University of Florence, Italy (Prof M Mannelli MD); Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development (Prof K Pacak MD); and Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke (G Eisenhofer PhD), National Institutes of Health, Bethesda, Maryland, USA

Correspondence to: Prof Jacques W M Lenders [j.lenders@aig.umcn.nl](mailto:j.lenders@aig.umcn.nl)

## Search strategy and selection criteria

We searched the databases PubMed and EMBASE (Jan 1, 2000, to May 1, 2005) using the following keywords: "phaeochromocytoma", "paraganglioma", and "extra-adrenal". We also included review articles, book chapters, or commonly referenced older publications. We reviewed the reference lists of articles identified by the search strategy and selected those we judged relevant. The search was restricted to papers published in English.

**Panel 1: Differential diagnosis of pheochromocytoma****Endocrine**

Hyperthyroidism  
 Carcinoid  
 Hypoglycaemia  
 Medullary thyroid carcinoma  
 Mastocytosis  
 Menopausal syndrome

**Cardiovascular**

Heart failure  
 Arrhythmias  
 Ischaemic heart disease  
 Baroreflex failure

**Neurological**

Migraine  
 Stroke  
 Diencephalic epilepsy  
 Meningioma  
 Postural orthostatic tachycardia syndrome (POTS)

**Miscellaneous**

Porphyria  
 Panic disorder or anxiety  
 Factitious disorders (eg, from use of sympathomimetic drugs such as ephedrine)  
 Drug treatment (eg, monoamine oxidase inhibitors, sympathomimetic drugs, withdrawal of clonidine)  
 Illegal drugs (eg, cocaine)

patients with predominantly epinephrine-secreting tumours present with hypotension or even shock.<sup>30</sup> Pathophysiological factors contributing to hypotension and shock, include intravascular volume depletion, abrupt cessation of catecholamine secretion due to tumour necrosis, desensitisation of adrenergic receptors, or hypocalcaemia.<sup>31</sup> Shock can also be caused by a complicating cardiovascular emergency, such as myocardial infarction, cardiac arrhythmias, or a dissecting aortic aneurysm. Other cardiovascular complications of pheochromocytoma include sudden death, heart failure due to toxic cardiomyopathy, hypertensive encephalopathy, a cerebrovascular accident, or neurogenic pulmonary oedema.<sup>32–34</sup> Since these disorders, when occurring without pheochromocytoma, are often accompanied by strong increments in plasma catecholamines, the exclusion or confirmation of an eventual underlying pheochromocytoma in these patients is especially difficult.

Paroxysmal signs and symptoms, a consequence of episodic secretion of catecholamines, provide compelling clues for a pheochromocytoma.<sup>17,20,21</sup> Anaesthesia and tumour manipulation are the most well-known stimuli to elicit a catecholaminergic crisis. Food, micturition (urinary bladder pheochromocytoma), and various

	Frequency
Headache	60–90%
Palpitations	50–70%
Sweating	55–75%
Pallor	40–45%
Nausea	20–40%
Flushing	10–20%
Weight loss	20–40%
Tiredness	25–40%
Psychological symptoms (anxiety, panic)	20–40%
Sustained hypertension	50–60%
Paroxysmal hypertension	30%
Orthostatic hypotension	10–50%
Hyperglycaemia	40%

Table adapted from references 17, 20, and 21. \*Frequency in patients tested because of signs and symptoms.

**Table 1: Frequency of signs and symptoms (%) of pheochromocytoma\***

chemical compounds or drugs (eg, glucagon, radiographic contrast substances, tyramine, metoclopramide, and tricyclic antidepressants) might also induce paroxysms. Such spells are usually unpredictable. For most patients they last between several minutes and 1 h.<sup>35,36</sup>

Despite improved diagnostic techniques that can bring about an earlier diagnosis of pheochromocytoma, there still usually remains a delay of 3 years between initial symptoms and a final diagnosis.<sup>18,27</sup> The most obvious reason for this delay is that in daily clinical patient care, the individual symptoms are quite non-specific—especially headaches, palpitations, and sweating, which are the most frequent. Nevertheless, if all three symptoms present together, the specificity of this combination is reported to be more than 90%.<sup>37</sup> Hypertension from a pheochromocytoma during pregnancy can mimic pre-eclampsia, so that the diagnosis is delayed or even missed entirely.

Advances in diagnosis and genetics now challenge the traditional rule of 10 for pheochromocytomas (10% bilateral, 10% extra-adrenal, 10% familial, 10% malignant). Prevalence of bilateral adrenal tumours is higher than 10% in some familial pheochromocytoma syndromes such as multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome.<sup>38</sup> Prevalence of extra-adrenal tumours can reach 20%,<sup>1,19</sup> and up to a quarter or more are hereditary.<sup>12–14,24</sup> Finally, although metastases might be rare for adrenal pheochromocytomas (up to 5%), the prevalence of malignant disease is about 33% for extra-adrenal pheochromocytomas and even higher in patients with specific mutations such as those causing some forms of familial paragangliomas (eg, *SDHB*, a gene that encodes the B subunit of mitochondrial succinate dehydrogenase).<sup>1,15,18,19,39</sup>

We further review here the advances in genetics, biochemical diagnosis, and tumour imaging techniques and how these advances affect the spectrum of disease presentations that must now be considered and the available options for disease management and treatment.

## Genetics of pheochromocytoma

Advances in genetics and recognition of the high prevalence of pheochromocytoma in certain familial syndromes led to mandatory routine screening in patients with identified mutations, even in the absence of typical clinical signs and symptoms.<sup>40</sup> Accumulating evidence also suggests that a hereditary basis for pheochromocytoma is more frequent than previously thought, accounting for up to 24% of patients with the tumour with no obvious initial evidence of a syndrome or family history.<sup>13,24,41</sup>

So far, germline mutations in five genes have been identified to be responsible for familial pheochromocytomas: the von Hippel-Lindau gene (*VHL*), which causes von Hippel-Lindau syndrome; the *RET* gene leading to multiple endocrine neoplasia type 2; the neurofibromatosis type 1 gene (*NF1*), which is associated with von Recklinghausen's disease; and the genes encoding the B and D subunits of mitochondrial succinate dehydrogenase (*SDHB* and *SDHD*), which are associated with familial paragangliomas and pheochromocytomas (table 2).<sup>14</sup> Pheochromocytomas are not always present and usually are not the first clinical manifestation of syndromes due to mutations of *VHL*, *RET*, and *NF1* genes. Pheochromocytomas in these three syndromes are usually associated with other benign or malignant neoplasms (panel 2).

### Von Hippel-Lindau syndrome

Renal clear-cell carcinomas and cysts, CNS and retinal hemangioblastomas, pheochromocytomas, pancreatic tumours and cysts, endolymphatic tumours, and epididymal cysts occur in von Hippel-Lindau syndrome, which affects about one in 36 000 livebirths.<sup>46–48</sup> Presentation of these clinical manifestations can vary, with two broad types (1 and 2) depending on the presence or absence of a family history of pheochromocytoma.<sup>47</sup> Overall, pheochromocytoma is present in 10–20% of patients with the syndrome, with a mean age at presentation of 30 years.<sup>47</sup> Pheochromocytomas in von Hippel-Lindau syndrome produce norepinephrine but not epinephrine. These tumours often have a bilateral adrenal presentation, and occasionally are multifocal with abdominal or thoracic localisations.<sup>24,49–51</sup> Malignant disease is rare, at about 5% or lower.<sup>42</sup>

### Multiple endocrine neoplasia type 2

In multiple endocrine neoplasia type 2, pheochromocytoma is the first clinical manifestation in 10–30% of patients, but penetrance is ultimately about 50%.<sup>52</sup> Pheochromocytomas in these patients produce both epinephrine and norepinephrine, with production of epinephrine occasionally predominating.<sup>51</sup> Most patients (50–80%) develop bilateral adrenal tumours, either simultaneously or at different times. Extra-adrenal localisation or malignant disease are very rare (<5%).<sup>16,24</sup>

	Chromosome	Exons	Protein	Frequency of germline mutations in apparent sporadic pheochromocytoma*	Frequency of malignant disease*
<i>VHL</i>	3p25-26	3	pVHL19 and pVHL30	2–11%	5%
<i>RET</i>	10q11.2	21	Tyrosine-kinase receptor	<5%	3%
<i>NF1</i>	17q11.2	59	Neurofibromin	Unknown	11%
<i>SDHB</i>	1p36.13	8	Catalytic iron-sulfur protein	3–10%	50%
<i>SDHD</i>	11q23	4	Cybs (membrane-spanning subunit)	4–7%	<3%

VHL= von Hippel-Lindau syndrome. \*Data from references 13, 24, and 42–45.

**Table 2: Characteristics of genes associated with familial forms of pheochromocytoma**

### Panel 2: Main clinical features of syndromes associated to pheochromocytoma

#### Von Hippel-Lindau syndrome

##### Type 1 (no pheochromocytoma)

- Renal-cell cysts and carcinomas
- Retinal and CNS haemangioblastomas
- Pancreatic neoplasms and cysts
- Endolymphatic sac tumours
- Epididymal cystadenomas

##### Type 2 (with pheochromocytoma)

- A: Retinal and CNS haemangioblastomas  
Pheochromocytomas  
Endolymphatic sac tumours  
Epididymal cystadenomas
- B: Renal-cell cysts and carcinomas  
Retinal and CNS haemangioblastomas  
Pancreatic neoplasms and cysts  
Pheochromocytomas  
Endolymphatic sac tumours  
Epididymal cystadenomas
- C: Pheochromocytomas only

#### Multiple endocrine neoplasia type 2

- A: Medullary thyroid carcinoma  
Pheochromocytoma  
Hyperparathyroidism  
Cutaneous lichen amyloidosis
- FMTC: Familial medullary thyroid carcinoma only
- B: Medullary thyroid carcinoma  
Pheochromocytoma  
Multiple neuromas  
Marfanoid habitus

#### Neurofibromatosis type 1

- Multiple fibromas on skin and mucosae
- "Café au lait" skin spots
- Pheochromocytomas

#### Paraganglioma syndromes

- Head and neck tumours (carotid-body tumours; vagal, jugular, and tympanic paragangliomas)
- Pheochromocytomas
- Abdominal or thoracic paragangliomas (or both)

### Neurofibromatosis type 1 syndrome

In neurofibromatosis type 1, pheochromocytoma is relatively rare (<5%). Because of this, routine screening for the tumour is not generally recommended. Genetic testing in members of an affected family is possible.<sup>24</sup> Pheochromocytomas in affected individuals usually produce both epinephrine and norepinephrine.

### Paraganglioma syndromes

The germline mutations of the succinate dehydrogenase gene family are the most recently identified hereditary causes of pheochromocytoma.<sup>43,53</sup> Mutations of each of the *SDHB* and *SDHD* genes have been seen in about 3–11% of patients with non-syndromic pheochromocytoma, mainly occurring as paragangliomas in the head, chest, and abdomen (panel 2).<sup>43,44</sup> Head and neck paragangliomas are more commonly associated with *SDHD* than with *SDHB* mutations.<sup>43,53</sup> Penetrance seems slightly higher and multifocal disease seems to be more frequently associated with *SDHD* than with *SDHB* mutations, but *SDHB* mutations are associated with an increased rate of malignant disease (up to 50%).<sup>44,45</sup> The chromaffin tumours due to mutations of both genes produce predominantly norepinephrine. Whether other malignant diseases are associated with *SDHB* mutations such as renal-cell carcinoma and thyroid papillary carcinoma is not currently clear.<sup>44</sup> *SDHD* mutations are maternally imprinted; thus, only carriers who have inherited the mutation from the father develop the disease and those who inherit from the mother are disease-free.<sup>54</sup>

### Genetic testing

Should genetic testing be propagated in all patients with a pheochromocytoma? It has been suggested that all patients with a pheochromocytoma should be considered for genetic testing.<sup>44,55</sup> The reasons are twofold. First, the syndromic hereditary forms of pheochromocytoma are associated with other neoplasms, so an early diagnosis of a hereditary syndrome might lead to regular surveillance and eventual treatment and thus improve the prognosis; this could extend to other family members with similar benefits. Second, in patients with proven germline mutations, multiple pheochromocytomas and recurrences are highly probable, so that a more stringent clinical follow-up is recommended throughout life. Presently, the indication for cost-effective genetic testing is recommended to those patients who have a positive family history or those who are younger than 50 years, especially children.<sup>24</sup> However, other clues that should be regarded as an indication for genetic testing include the presence of bilateral pheochromocytomas or multifocal extra-adrenal disease, or the association of pheochromocytomas with other tumours. Direction of genetic testing to one of the suspected genes can benefit from consideration of the clinical picture and

biochemical phenotype of the tumour: bilateral epinephrine-producing tumours or the association of pheochromocytoma with medullary thyroid carcinoma indicate the need for *RET* analysis; predominantly norepinephrine-producing pheochromocytomas—especially if bilateral or in association with renal-cell carcinoma or cysts, retinal or cerebrospinal haemangioblastomas, or pancreatic tumours—indicate *VHL* testing; and the association between chromaffin tumours and head or neck paragangliomas indicates analysis of *SDHB* or *SDHD* genes.

If genetic testing is negative in a patient with pheochromocytoma, only biochemical testing for recurrence of the tumour after surgery is needed. When genetic testing is negative in a family member of a patient with a hereditary form of pheochromocytoma, no additional biochemical or imaging tests are necessary.

## Biochemical diagnosis and localisation

### Biochemical testing

All patients with suspected pheochromocytoma should undergo biochemical testing. These include patients with paroxysmal signs or symptoms suggestive of a pheochromocytoma; patients with recent, therapy-resistant, or volatile hypertension; patients with a paradoxical blood pressure response during surgery and anaesthesia; patients with a hereditary predisposition for a pheochromocytoma; asymptomatic patients with an adrenal incidentaloma; and patients with sudden attacks of anxiety. Because of the low prevalence of pheochromocytoma, biochemical screening for the tumour in asymptomatic patients with hypertension is not indicated.

Biochemical presentation of excessive production of catecholamines is an essential step for the diagnosis of pheochromocytoma. Traditional biochemical tests include measurements of urinary and plasma catecholamines, urinary metanephrines (normetanephrine and metanephrine), and urinary vanillylmandelic acid (VMA). Measurements of plasma-free metanephrines (normetanephrine and metanephrine) represent a more recently available test.<sup>56</sup> Because of insufficient sensitivity and specificity, chromogranin A has no additional benefit over the use of catecholamines or their metabolites for initial diagnosis of pheochromocytoma.<sup>57–59</sup>

The potentially fatal consequences of a missed diagnosis justify the need for a high level of reliability of a positive test result in that rare patient with the tumour. This conversely also provides confidence that a negative test result reliably excludes the tumour. The initial examination of a patient with suspected pheochromocytoma should therefore include a suitably sensitive biochemical test. Either blood or urine testing can be used, with each test having its own advantages and disadvantages. Accumulating evidence suggests that

measurements of plasma-free metanephrines or urinary-fractionated metanephrines (normetanephrine and metanephrine separately) are the most sensitive tests for diagnosis, and are the most suitable for reliable exclusion of pheochromocytoma (table 3).<sup>50,60-66</sup> Increased sensitivity of metanephrines compared with catecholamines is due to the continuous production of O-methylated metabolites in tumours from catecholamines leaking from chromaffin stores. The production of O-methylated metabolites is independent of the highly variable release of catecholamines.<sup>67,68</sup> Although tumours produce and metabolise catecholamines, they do not always release catecholamines. Provided appropriate reference intervals are used, the high diagnostic sensitivities of plasma-free or urinary-fractionated metanephrines mean that negative test results exclude the presence of virtually all pheochromocytomas. Exceptions include asymptomatic small tumours that produce and metabolise negligible amounts of norepinephrine or epinephrine.

As with all biochemical tests of catecholamine excess, a remaining difficulty is that a positive result for plasma or urinary metanephrines does not always reliably indicate a pheochromocytoma. The many physiological stimuli, drugs, and clinical conditions that cause increases in circulating catecholamines and metabolites compound this problem. The rarity of the tumour in tested patients, many of whom have symptoms associated with increased sympathetic activity and circulating catecholamines (eg, hypertension, heart failure, stroke, baroreflex failure, cardiogenic shock), also means that false-positive results exceed true-positive results.

Most true-positive results can be distinguished from false-positive test results from the magnitude of increases in test results above reference intervals (table 4). Most patients with pheochromocytoma have increases well above even the highest false-positive results. In these patients, diagnosis is straightforward. Further confirmation can be achieved by the demonstration of similar patterns of increased plasma and urinary normetanephrine and metanephrine or repeat testing with an alternative method.

The major remaining difficulties are patients with smaller increases (less than two to three times the upper reference limits), most of whom will not have pheochromocytoma. Drugs, dietary interferences, or inappropriate sampling conditions are causes of false-positive results. False-positive results could arise either due to direct interference with analytical methods or pharmacological effects on the disposition of catecholamines (table 5). Interference with analytical methods is highly variable from method to method. Avoidance of such interference needs intimate knowledge of the procedures used and how various drugs can affect them. Pharmacological effects on the disposition of catecholamines are independent of the measurement method and can be avoided by the

	Sensitivity	Specificity
Plasma-free metanephrines	99%	89%
Plasma catecholamines	84%	81%
Urinary catecholamines	86%	88%
Urinary-fractionated metanephrines	97%	69%
Urinary total metanephrines	77%	93%
VMA	64%	95%

Sensitivity values of all tests for familial pheochromocytoma are lower than that for sporadic pheochromocytomas; the reverse is the case for specificity values. Table adapted from reference 64.

**Table 3: Sensitivity and specificity of biochemical tests for diagnosis of pheochromocytoma**

withdrawal or substitution of drugs known to cause increases in catecholamines and their metabolites. Phenoxybenzamine (used to treat patients with suspected pheochromocytoma) and tricyclic antidepressants are major causes of false-positive results, in one study accounting for up to 45% of false-positive increments of urinary and plasma normetanephrine and norepinephrine.<sup>69</sup> Sampling of blood after overnight fasting and in the supine position can easily avoid the effects of diet and physical activity on plasma measurements. For urine measurements, timed or overnight urine samples or volume correction using additional measurements of creatinine can avoid difficulties with incomplete or overzealous collection of urine.<sup>66</sup>

Use of clonidine to suppress catecholamine release from the sympathoadrenal system provides a dynamic

	Presence of pheochromocytoma		
	Unlikely*	Possible	Likely†
<b>Urine tests</b>			
Catecholamines (HPLC)			
Norepinephrine (nmol/24 h)	<500	500-1180	>1180
Epinephrine (nmol/24 h)	<100	100-170	>170
Fractionated metanephrines (HPLC)			
Normetanephrine (nmol/24 h)	<3000	3000-6550	>6550
Metanephrine (nmol/24 h)	<1000	1000-2880	>2880
Total metanephrines (spectrophotometry)			
Total of normetanephrine and metanephrine (µmol/24 h)	<6	6-12.7	>12.7
VMA (spectrophotometry)			
VMA (µmol/24 h)	<40	40-55	>55
<b>Blood tests</b>			
Catecholamines (HPLC)			
Noradrenaline (nmol/L)	<3.00	3.00-7.70	>7.70
Adrenaline (nmol/L)	<0.45	0.45-1.20	>1.20
Free metanephrines (HPLC)			
Normetanephrine (nmol/L)	<0.60	0.60-1.40	>1.40
Metanephrine (nmol/L)	<0.30	0.30-0.42	>0.42

HPLC=high-pressure liquid chromatography. Unlikely=number of true-negative results>>number of false-negative results; possible=false-positive results>true-positive results; likely=true-positive results>>>false-positive results. \*Cut-off points represent upper reference limits used for estimation of sensitivity and specificity in table 3; therefore, the negative predictive value (ie, likelihood that pheochromocytoma is not present) varies for every test, depending on differences in the test characteristics in table 3. †Cut-off points are calculated from 99th percentile in a reference group of 644 patients who had no pheochromocytoma. Table adapted from reference 64.

**Table 4: Likelihood of pheochromocytoma at different cut-off points for biochemical tests of catecholamine excess**

	Nature of interference
<b>Analytical methods</b>	
Coffee (including decaffeinated coffee)	HPLC assays: plasma catecholamines
Labetalol	Spectrophotometric and fluorometric assays: urinary catecholamines and metanephrines;
Sotalol	HPLC assays: plasma catecholamines
Buspirone	HPLC assays: urinary metanephrines
Paracetamol	HPLC assays: plasma-free metanephrines
Levodopa	HPLC assays: catecholamines and metabolites
$\alpha$ -methyl dopa	HPLC assays: catecholamines
Sympathomimetics (eg, amfetamines, ephedrine)	Spectrophotometric and fluorometric assays: plasma and urinary catecholamines
<b>Pharmacodynamic or pharmacokinetic interference</b>	
Tricyclic antidepressants	Blocks norepinephrine reuptake, causing rises in plasma and urinary norepinephrine, normetanephrine, and VMA
Phenoxybenzamine	Blocks presynaptic $\alpha$ 2 adrenoceptors, causing increases in plasma and urinary norepinephrine, normetanephrine, and VMA
Monoamine oxidase inhibitors	Blocks deamination, causing up to five-fold increases in plasma and urinary metanephrines
Levodopa	Metabolised by enzymes that also convert catecholamines
$\alpha$ -methyl dopa	Metabolised by enzymes that also convert catecholamines
Stimulants (eg, caffeine, nicotine)	Increased plasma and urinary catecholamines
Sympathomimetics (eg, amfetamines, ephedrine)	Increased plasma and urinary catecholamines
Calcium-channel blockers (dihydropyridines)	Increased plasma catecholamines due to sympathetic activation

HPLC=high-pressure liquid chromatography.

**Table 5: Sources of variable interference with measurements of catecholamines and catecholamine metabolites**

pharmacological test to distinguish increased catecholamine release due to sympathetic activation from increased release due to phaeochromocytomas.<sup>70</sup> Failure to suppress plasma norepinephrine (ie, a reduction of <50% from basal or consistently raised basal plasma concentrations of >3 nmol/L) after clonidine is highly predictive for phaeochromocytoma (97%). By contrast, the negative predictive value of a normal test result is only 75%. If plasma normetanephrine is used (of which a failure to suppress is a reduction of less than 40% from basal or consistently raised basal concentrations of plasma normetanephrine of more than 0.60 nmol/L) instead of plasma norepinephrine, the positive and negative predictive values of this test improve to 100% and 96%, respectively.<sup>69</sup> Thus, although absence of suppression of plasma norepinephrine or normetanephrine both provide strong evidence for phaeochromocytoma, only the suppression of normetanephrine provides reasonable evidence that a phaeochromocytoma is not present.

### Imaging procedures

Tumour localisation should ideally only be initiated once there is unequivocal biochemical evidence for phaeochromocytoma. CT scans of the entire abdomen (including pelvis), with and without contrast, are most often used for initial localisation of adrenal or possible extra-adrenal abdominal phaeochromocytomas.<sup>71</sup>

Evidence from one small study indicates that contrast-enhancement with iohexol has no effect on plasma catecholamines.<sup>72</sup> Until this finding is confirmed, patients should be protected from a hypertensive crisis or cardiac arrhythmia by combined blockade by  $\alpha$  and  $\beta$  adrenoceptors. Although T2-weighted MRI with gadolinium enhancement has a similar diagnostic sensitivity to CT scanning, it is preferred for the localisation of extra-adrenal tumours or tumours during pregnancy, in children, or in patients with allergies to contrast.<sup>1,73,74</sup> No adrenergic blockade is needed.<sup>71</sup> Since CT scanning and MRI have similar sensitivities (90–100%) and specificities (70–80%), MRI is the preferred procedure.<sup>2,71</sup>

Because of the restricted specificities of CT and MRI, identification of a mass detected by these techniques can be achieved by use of the increased specificity (95–100%) of <sup>123</sup>I-metaiodobenzylguanidine (MIBG) scanning.<sup>2,75</sup> If <sup>123</sup>I-MIBG is not available, <sup>131</sup>I-MIBG could be used as an alternative, but has poorer imaging qualities than <sup>123</sup>I-MIBG.<sup>76</sup> The coupling of functional with anatomical imaging might also be valuable for the detection of additional multifocal or metastatic tumours, which can be important for appropriate guiding of subsequent management and treatment. However, <sup>123</sup>I-MIBG scanning might not be warranted before surgery in all patients with biochemically proven phaeochromocytomas. Such imaging is most relevant in patients with extra-adrenal or large (>5 cm) adrenal tumours with increased risk of malignant disease,<sup>77</sup> or in patients with high suspicion of the presence of multifocal disease.

Several drugs (eg, labetalol, tricyclic antidepressants, and specific calcium antagonists) can interfere with tumour uptake or retention of <sup>123</sup>I-MIBG.<sup>78</sup> Temporary withdrawal of these interfering drugs (five times their half-lives) or use of other drugs can avoid false-negative test results. In patients whose <sup>123</sup>I-MIBG scans are negative, <sup>111</sup>In-octreotide scanning might be useful in case no other functional imaging techniques are available.<sup>79,80</sup> Small recurrent tumours or metastases in the adrenal region can be detected intraoperatively by a  $\gamma$ -detector probe after the isotope is given a few hours before surgery.<sup>81</sup>

PET with <sup>18</sup>F-fluorodopamine, <sup>18</sup>F-fluorodopa, <sup>18</sup>F-fluorodeoxyglucose, or <sup>11</sup>C-hydroxyephedrine are other functional imaging methods that can be used as alternatives to <sup>123</sup>I-MIBG or as additional procedures if <sup>123</sup>I-MIBG scanning is negative.<sup>82–85</sup> <sup>18</sup>F-fluorodeoxyglucose, the only PET imaging compound that is widely available, is not recommended for initial diagnostic localisation, since it is non-specific for phaeochromocytoma and sensitivity is restricted.<sup>82</sup> However, the compound can be useful if other imaging procedures are negative, often in more rapidly growing dedifferentiated tumours that have lost the ability to accumulate more specific drugs.<sup>82,86</sup> <sup>18</sup>F-fluorodopamine PET offers better diagnostic sensitivity than <sup>131</sup>I-MIBG scintigraphy, especially in metastatic phaeochromocytomas where the compound

can localise far more foci than can  $^{131}\text{I}$ -MIBG.<sup>86,87</sup>  $^{18}\text{F}$ -fluorodopa and  $^{11}\text{C}$ -hydroxyephedrine have also been reported to offer excellent sensitivity and specificity, but how useful these drugs are for metastatic phaeochromocytomas is unclear.<sup>83,84</sup>

## Management of phaeochromocytoma

### Preoperative management

Once a phaeochromocytoma is located, complications during surgery need to be kept to a minimum by appropriate preoperative medical treatment. With adequate pretreatment, perioperative mortality has fallen to less than 3%, which emphasises the importance for adequate preoperative management.<sup>12,88,89</sup> The major aim of medical pretreatment is to prevent catecholamine-induced, serious, and potentially life-threatening complications during surgery, including hypertensive crises, cardiac arrhythmias, pulmonary oedema, and cardiac ischaemia.<sup>89-91</sup> Even if a diagnosis is considered in very rare life-threatening conditions (eg, shock due to a haemorrhagic necrosis or rupture of a phaeochromocytoma), stabilisation with subsequent medical pretreatment and elective surgery is preferred, since emergency tumour resection without proper preparation results in poor survival.<sup>92</sup>

There are no randomised prospective studies that are large enough to establish the most effective drug regimen before surgery. Traditional regimens include the blockade of  $\alpha$ -adrenoceptors with phenoxybenzamine, prazosin, doxazosin, or urapidil.<sup>93-95</sup> Phenoxybenzamine is often preferred because it blocks  $\alpha$ -adrenoceptors non-competitively. This type of blocking offers advantages over competitive blockade with compounds such as doxazosin, which avoids drug displacement from  $\alpha$ -adrenoceptors by excessive increases in catecholamines during surgery. However, several groups have advocated pretreatment with doxazosin, based on a presumed increased risk of postoperative hypotension due to extended, non-competitive  $\alpha$ -adrenergic blockade.<sup>19,96</sup> But several retrospective, non-randomised clinical trials comparing phenoxybenzamine with prazosin or doxazosin have provided conflicting results.<sup>97-99</sup>

Other alternative drugs for preoperative management are labetalol or calcium-channel blockers (dihydropyridines), either alone or in combination with  $\alpha$ -adrenergic receptor blockers.<sup>100</sup> Labetalol is a combined  $\alpha$  and  $\beta$ -adrenoceptor blocker with stronger actions on  $\beta$  than  $\alpha$ -adrenoceptors. Therefore, this drug is less suitable for pretreatment than other  $\alpha$ -adrenoceptor blockers. Calcium-channel blockers have the advantage of not causing orthostatic hypotension, but if used alone they do not prevent haemodynamic instability completely.  $\alpha$ -methyl-paratyrosine (metirosine), which blocks catecholamine synthesis, is occasionally used for preoperative treatment. Two retrospective studies showed that use of metirosine as an adjunct to

phenoxybenzamine needed less antihypertensive drug treatment during surgery than did the sole use of phenoxybenzamine, but this finding has not been verified by any prospective study.<sup>101,102</sup>

Pretreatment with an  $\alpha$ -adrenergic blocker can usually be undertaken on an outpatient basis and is safe in most patients.<sup>103</sup> Treatment usually lasts for 10–14 days.<sup>88</sup> The initial dose of phenoxybenzamine is 10 mg twice a day. The dose is increased every 2–3 days by 10–20 mg to a total daily dose of 1 mg/kg, which is sufficient in most patients. Doxazosin is given in increasing doses from 1 to 16 mg once a day.<sup>93</sup> A  $\beta$ -adrenoceptor blocker (eg, propranolol 40 mg three times daily or atenolol 25–50 mg once daily) could be included after several days of  $\alpha$ -adrenergic blockade. This addition is especially useful in patients who also have tachyarrhythmias. Blockade of  $\beta$ -adrenoceptors should never be initiated before blockade of  $\alpha$ -adrenoceptors, since the loss of  $\beta$ -adrenoceptor-mediated vasodilatation leaves  $\alpha$ -adrenoceptor stimulation unopposed, which could result in hypertensive crises.

To ensure adequate preoperative preparation, several criteria have been proposed: blood pressure should be reduced to below 160/90 mm Hg for at least 24 h; orthostatic hypotension should be present, but blood pressure in the upright position should not fall below 80/45 mm Hg; there should be no more than one ventricular extrasystole every 5 min; and the electrocardiogram should show no S-T segment changes and T-wave inversions for 1 week.<sup>88</sup>

Risk of excessive orthostatic hypotension can be kept to a minimum by the increase of salt and fluid intake. The additional advantage of this approach is that it reduces the risk of postoperative hypotension. Should substantial rises in blood pressure still take place during surgery, these can be controlled by bolus or by continuous infusion of phentolamine, sodium nitroprusside, or a shortacting calcium antagonist (eg, nicardipine); tachyarrhythmias can be treated by infusion of a shortacting  $\beta$ -adrenoceptor blocker (eg, esmolol).<sup>93,96</sup>

After surgery, patients need to be under close surveillance for the first 24 h in an intensive or intermediate care unit. The two major postoperative complications are hypotension and hypoglycaemia. Postoperative hypotension is due to the abrupt fall in circulating catecholamines after tumour removal in the continuing presence of  $\alpha$ -adrenoceptor blockade (by phenoxybenzamine). Treatment consists of fluid replacement and occasionally intravenous ephedrine. If ephedrine infusion is ineffective, vasopressin might be used.<sup>104</sup> The risk of hypoglycaemia is related to rebound hyperinsulinaemia due to the recovery of insulin release after tumour removal.<sup>93</sup>

### Surgical treatment

Laparoscopic removal of intra-adrenal and extra-adrenal phaeochromocytomas is now the preferred surgical

technique.<sup>105</sup> Data from observational studies clearly show that the laparoscopic procedure reduces postoperative morbidity, hospital stay, and expense compared with conventional laparotomy.<sup>106–112</sup> The complication rate of laparoscopic adrenalectomy (apart from intraoperative blood pressure derailments) is probably less than 8% with a conversion rate of 5%.<sup>109,113,114</sup> Some clinicians recommend a retroperitoneal laparoscopic approach for suprarenal paragangliomas and a transperitoneal laparoscopic approach for infrarenal paragangliomas.<sup>110</sup>

Because of the high incidence of bilateral adrenal disease in familial pheochromocytoma (eg, von Hippel-Lindau and multiple endocrine neoplasia type 2 syndromes), adrenal-cortex-sparing laparoscopic surgery (partial adrenalectomy) has been advocated to save the cortex and prevent permanent glucocorticoid deficiency.<sup>115–121</sup>

Currently, after adequate medical preparation, operative mortality is less than 1% if undertaken by an experienced anaesthesiologist and a skilful surgeon.<sup>114,117,122</sup> The long-term prognosis of patients after resection of a solitary sporadic pheochromocytoma is excellent, although hypertension might persist after surgery in nearly 50% of patients.<sup>123</sup> Findings from a large study with a long-term follow-up showed a recurrence rate of 17%, with half the patients showing signs of malignant disease.<sup>27</sup> Recurrences occurred more often in patients with extra-adrenal disease (33%) than in those with adrenal disease (14%), and more often in the familial population (33%) than in the non-familial population (13%).<sup>124</sup> In patients who have undergone adrenal cortex-sparing surgery, a small piece of tumour could have been left behind or a new tumour could develop in the remnant because of a genetic predisposition. The risk of tumour recurrence in the remnant adrenal gland is 10%, but the metachronous tumour development in the contralateral adrenal gland is 30% in patients with hereditary forms of pheochromocytoma.<sup>116,119,124</sup> All patients should be followed up every year for at least 10 years after surgery. Patients with extra-adrenal or familial pheochromocytoma should be followed up indefinitely.

### Malignant pheochromocytomas

Despite the increasing availability of molecular diagnostic and prognostic markers, it remains impossible to predict the subsequent development of malignant disease, based on histological findings in a resected tumour.<sup>125,126</sup> Not one histological feature predicts or provides unequivocal evidence of malignant derangement. Only the presence of metastases of chromaffin tissue at sites where no chromaffin tissue should be expected establishes a definite diagnosis of malignant pheochromocytoma. The most common metastatic sites are the bones, lungs, liver, and lymph nodes. In general, tumours that are large (>5 cm) or

have an extra-adrenal location have a higher risk for malignant disease than tumours that are small or have an adrenal location.<sup>19</sup> Paragangliomas in patients with *SDHB* mutations have a particularly high rate of malignant disease.<sup>52,53</sup> Increased plasma or urinary concentrations of dopamine and dihydroxyphenylalanine (dopa) arise more often in malignant than in benign pheochromocytomas.<sup>127–129</sup> When malignant disease is confirmed, the natural clinical course is highly variable in patients with 5-year survival rates of 50%.<sup>126</sup>

There remains no effective treatment for malignant pheochromocytoma. Radical surgical removal of tumour tissue is the mainstay to improve symptoms and survival, but there are no randomised studies that support this approach. Symptomatic treatment can be obtained with  $\alpha$ -adrenergic blockers.  $\alpha$ -methyl-paratyrosine can be useful in selected patients with very high concentrations of circulating catecholamines. Treatment with <sup>131</sup>I-MIBG or combination chemotherapy (cyclophosphamide, vincristine, and dacarbazine) has shown disappointing results, with only shortlasting remissions.<sup>130–132</sup> Although nearly 80% of patients show symptomatic improvement after <sup>131</sup>I-MIBG treatment, less than 5% have a complete remission and 30% have a partial tumour remission.<sup>131,132</sup> Improved long-term survival has been shown with increased doses of <sup>131</sup>I-MIBG.<sup>133</sup> However, controlled studies need to confirm these results and establish whether combination treatment of <sup>131</sup>I-MIBG with myeloablative chemotherapy (and stem cell rescue) can improve prospects of patients with metastatic disease.

### Conflict of interest statement

We declare that we have no conflict of interest.

### References

- Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. *J Urol* 1992; **147**: 1–10.
- Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. *Ann Intern Med* 2001; **134**: 315–29.
- Erickson D, Kudva YC, Ebersold MJ, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. *J Clin Endocrinol Metab* 2001; **86**: 5210–16.
- Coupland R. The natural history of the chromaffin cell. Essex, UK: Longman Green and Co, 1965.
- Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. *J Hypertens* 1994; **12**: 609–15.
- Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. *Hypertens Res* 2004; **27**: 193–202.
- Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. *Arch Intern Med* 1987; **147**: 1289–93.
- Platts JK, Drew PJ, Harvey JN. Death from pheochromocytoma: lessons from a post-mortem survey. *J R Coll Physicians Lond* 1995; **29**: 299–306.
- McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM. Pheochromocytomas discovered during coronal autopsies in Sydney, Melbourne and Auckland. *Aust N Z J Med* 2000; **30**: 648–52.

- 10 Lo CY, Lam KY, Wat MS, Lam KS. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. *Am J Surg* 2000; **179**: 212–15.
- 11 Khorram-Manesh A, Ahlman H, Nilsson O, Oden A, Jansson S. Mortality associated with pheochromocytoma in a large Swedish cohort. *Eur J Surg Oncol* 2004; **30**: 556–59.
- 12 Plouin PF, Duclos JM, Soppelsa F, Boubllil G, Chatellier G. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. *J Clin Endocrinol Metab* 2001; **86**: 1480–86.
- 13 Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. *N Engl J Med* 2002; **346**: 1459–66.
- 14 Maher ER, Eng C. The pressure rises: update on the genetics of pheochromocytoma. *Hum Mol Genet* 2002; **11**: 2347–54.
- 15 O'Riordain DS, Young WF Jr, Grant CS, Carney JA, van Heerden JA. Clinical spectrum and outcome of functional extraadrenal paraganglioma. *World J Surg* 1996; **20**: 916–21.
- 16 Neumann HP, Berger DP, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. *N Engl J Med* 1993; **329**: 1531–38.
- 17 Manger WM, Gifford RW. Clinical and experimental pheochromocytoma. second ed. Cambridge: Blackwell Sciences, 1996.
- 18 Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: a multicentric retrospective study. *Eur J Endocrinol* 1999; **141**: 619–24.
- 19 Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. *Endocr Rev* 2003; **24**: 539–53.
- 20 Werbel SS, Ober KP. Pheochromocytoma. Update on diagnosis, localization, and management. *Med Clin North Am* 1995; **79**: 131–53.
- 21 Kebebew E, Duh QY. Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-up. *Surg Oncol Clin N Am* 1998; **7**: 765–89.
- 22 Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients. *J Hypertens* 2003; **21**: 1703–07.
- 23 Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. *J Clin Endocrinol Metab* 2000; **85**: 637–44.
- 24 Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL. Pheochromocytoma: the expanding genetic differential diagnosis. *J Natl Cancer Inst* 2003; **95**: 1196–204.
- 25 Baguet JP, Hammer L, Mazzucco TL, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. *Eur J Endocrinol* 2004; **150**: 681–86.
- 26 Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. *Endocr Rev* 2004; **25**: 309–40.
- 27 Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. *J Clin Endocrinol Metab* 2005; **90**: 2110–16.
- 28 Eisenhofer G, Goldstein DS, Sullivan P, et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. *J Clin Endocrinol Metab* 2005; **90**: 2068–75.
- 29 Proye C, Fossati P, Fontaine P, et al. Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. *Surgery* 1986; **100**: 1154–62.
- 30 Bergland BE. Pheochromocytoma presenting as shock. *Am J Emerg Med* 1989; **7**: 44–48.
- 31 Olson SW, Deal LE, Piesman M. Epinephrine-secreting pheochromocytoma presenting with cardiogenic shock and profound hypocalcemia. *Ann Intern Med* 2004; **140**: 849–51.
- 32 Schurmeyer TH, Engeroff B, Dralle E, von zur Muhlen A. Cardiological effects of catecholamine-secreting tumors. *Eur J Clin Invest* 2005; **27**: 189–95.
- 33 Liao WB, Liu CF, Chiang CW, Kung CT, Lee CW. Cardiovascular manifestations of pheochromocytoma. *Am J Emerg Med* 2000; **18**: 622–25.
- 34 Brouwers FM, Lenders JW, Eisenhofer G, Pacak K. Pheochromocytoma as an endocrine emergency. *Rev Endocr Metab Disord* 2003; **4**: 121–28.
- 35 Sheps SG, Jiang NS, Klee GG. Diagnostic evaluation of pheochromocytoma. *Endocrinol Metab Clin North Am* 1988; **17**: 397–414.
- 36 Pacak K, Chrousos GP, Koch CA, Lenders JWM, Eisenhofer G. Pheochromocytoma. Progress in diagnosis, treatment and genetics. In: Margioris AN, Chrousos GP, eds. 1st edn. Totowa, NJ, USA: Humana Press, 2001: 379–413.
- 37 Plouin PF, Degoulet P, Tugaye A, Ducrocq MB, Menard J. [Screening for phaeochromocytoma in which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma (author's trans)]. *Nouv Presse Med* 1981; **10**: 869–72.
- 38 Kaltsas GA, Papadogias D, Grossman AB. The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas). *Front Horm Res* 2004; **31**: 61–75.
- 39 Edstrom EE, Hjelm Skog AL, Hoog A, Hamberger B. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. *Eur J Surg Oncol* 2003; **29**: 278–83.
- 40 Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. *J Clin Endocrinol Metab* 2001; **86**: 5658–71.
- 41 Bauters C, Vantyghem MC, Leteurtre E, et al. Hereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes. *J Med Genet* 2003; **40**: e75.
- 42 Walther MM, Reiter R, Keiser HR, et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. *J Urol* 1999; **162**: 659–64.
- 43 Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. *J Med Genet* 2002; **39**: 178–83.
- 44 Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. *JAMA* 2004; **292**: 943–51.
- 45 Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. *Cancer Res* 2003; **63**: 5615–21.
- 46 Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B. von Hippel-Lindau disease: genetic, clinical, and imaging features. *Radiology* 1995; **194**: 629–42.
- 47 Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. *Lancet* 2003; **361**: 2059–67.
- 48 Hes FJ, Hoppener JW, Lips CJ. Clinical review 155: pheochromocytoma in von Hippel-Lindau disease. *J Clin Endocrinol Metab* 2003; **88**: 969–74.
- 49 Richard S, Chauveau D, Chretien Y, et al. Renal lesions and pheochromocytoma in von Hippel-Lindau disease. *Adv Nephrol Necker Hosp* 1994; **23**: 1–27.
- 50 Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. *N Engl J Med* 1999; **340**: 1872–79.
- 51 Eisenhofer G, Walther MM, Huynh TT, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. *J Clin Endocrinol Metab* 2001; **86**: 1999–2008.
- 52 Modigliani E, Vasen HM, Raue K, et al. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. *J Intern Med* 1995; **238**: 363–67.
- 53 Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. *Am J Hum Genet* 2001; **69**: 49–54.
- 54 Baysal BE. Genomic imprinting and environment in hereditary paraganglioma. *Am J Med Genet C Semin Med Genet* 2004; **129**: 85–90.
- 55 Favier J, Briere JJ, Strompf L, et al. Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. *Horm Res* 2005; **63**: 171–79.

- 56 Lenders JW, Eisenhofer G, Armando I, Keiser HR, Goldstein DS, Kopin IJ. Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. *Clin Chem* 1993; **39**: 97–103.
- 57 Canale MP, Bravo EL. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. *J Clin Endocrinol Metab* 1994; **78**: 1139–44.
- 58 Boomsma F, Bhaggoe UM, Man in 't Veld AJ, Schalekamp MA. Sensitivity and specificity of a new ELISA method for determination of chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma. *Clin Chim Acta* 1995; **239**: 57–63.
- 59 Bernini GP, Moretti A, Ferdeghini M, et al. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours. *Br J Cancer* 2001; **84**: 636–42.
- 60 Gerlo EA, Sevens C. Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocytoma: diagnostic value in 19 cases. *Clin Chem* 1994; **40**: 250–56.
- 61 Raber W, Raffesberg W, Bischof M, et al. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. *Arch Intern Med* 2000; **160**: 2957–63.
- 62 Gardet V, Gatta B, Simonnet G, et al. Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. *J Hypertens* 2001; **19**: 1029–35.
- 63 Davidson DF. Pheochromocytoma with normal urinary catecholamines: the potential value of urinary free metadrenalines. *Ann Clin Biochem* 2002; **39**: 557–66.
- 64 Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? *JAMA* 2002; **287**: 1427–34.
- 65 Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. *J Clin Endocrinol Metab* 2003; **88**: 553–58.
- 66 Peaston RT, Weinkove C. Measurement of catecholamines and their metabolites. *Ann Clin Biochem* 2004; **41**: 17–38.
- 67 Eisenhofer G, Keiser H, Friberg P, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. *J Clin Endocrinol Metab* 1998; **83**: 2175–85.
- 68 Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. *Pharmacol Rev* 2004; **56**: 331–49.
- 69 Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. *J Clin Endocrinol Metab* 2003; **88**: 2656–66.
- 70 Bravo EL, Tarazi RC, Fouad FM, Vidt DG, Gifford RW Jr. Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. *N Engl J Med* 1981; **305**: 623–26.
- 71 Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. *J Clin Endocrinol Metab* 2004; **89**: 479–91.
- 72 Mukherjee JJ, Peppercorn PD, Reznick RH, et al. Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels. *Radiology* 1997; **202**: 227–31.
- 73 Mayo-Smith WW, Dupuy DE. Adrenal neoplasms: CT-guided radiofrequency ablation—preliminary results. *Radiology* 2004; **231**: 225–30.
- 74 Sahdev A, Sohaib A, Monson JP, Grossman AB, Chew SL, Reznick RH. CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas). *Eur Radiol* 2005; **15**: 85–92.
- 75 Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. *J Nucl Med* 1985; **26**: 576–85.
- 76 Furuta N, Kiyota H, Yoshigoe F, Hasegawa N, Ohishi Y. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. *Int J Urol* 1999; **6**: 119–24.
- 77 Miskulin J, Shulkin BL, Doherty GM, Sisson JC, Burney RE, Gauger PG. Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma? *Surgery* 2003; **134**: 918–22.
- 78 Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). *Nucl Med Commun* 1992; **13**: 513–21.
- 79 Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. *J Clin Endocrinol Metab* 2001; **86**: 895–902.
- 80 van der Harst E, de Herder WW, Bruining HA, et al. [(123I)]metaiodobenzylguanidine and [(111In)]octreotide uptake in benign and malignant pheochromocytomas. *J Clin Endocrinol Metab* 2001; **86**: 685–93.
- 81 Adams S, Acker P, Lorenz M, Staib-Sebler E, Hor G. Radioisotope-guided surgery in patients with pheochromocytoma and recurrent medullary thyroid carcinoma: a comparison of preoperative and intraoperative tumor localization with histopathologic findings. *Cancer* 2001; **92**: 263–70.
- 82 Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. *Radiology* 1999; **212**: 35–41.
- 83 Hoegerle S, Nitzsche E, Althoefer C, et al. Pheochromocytomas: detection with 18F DOPA whole body PET—initial results. *Radiology* 2002; **222**: 507–12.
- 84 Trampal C, Engler H, Juhlin C, Bergstrom M, Langstrom B. Pheochromocytomas: detection with 11C hydroxyephedrine PET. *Radiology* 2004; **230**: 423–28.
- 85 Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. *Endocr Rev* 2004; **25**: 568–80.
- 86 Ilias I, Yu J, Carrasquillo JA, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. *J Clin Endocrinol Metab* 2003; **88**: 4083–87.
- 87 Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. *Hypertension* 2001; **38**: 6–8.
- 88 Roizen MF, Schreider BD, Hassan SZ. Anesthesia for patients with pheochromocytoma. *Anesthesiol Clin North Am* 1987; **5**: 269–75.
- 89 Kinney MA, Warner ME, vanHeerden JA, et al. Perioperative risks and outcomes of pheochromocytoma and paraganglioma resection. *Anesth Analg* 2000; **91**: 1118–23.
- 90 Quezaco ZN, Keiser HR, Parker MM. Reversible myocardial depression after massive catecholamine release from a pheochromocytoma. *Crit Care Med* 1992; **20**: 549–51.
- 91 Tauzin-Fin P, Hilbert G, Krol-Houdek M, Gosse P, Maurette P. Mydriasis and acute pulmonary oedema complicating laparoscopic removal of pheochromocytoma. *Anaesth Intensive Care* 1999; **27**: 646–49.
- 92 Kobayashi T, Iwai A, Takahashi R, Ide Y, Nishizawa K, Mitsumori K. Spontaneous rupture of adrenal pheochromocytoma: review and analysis of prognostic factors. *J Surg Oncol* 2005; **90**: 31–35.
- 93 Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. *J Cardiothorac Vasc Anesth* 2002; **16**: 359–69.
- 94 Tauzin-Fin P, Sesay M, Gosse P, Ballanger P. Effects of perioperative alpha1 block on haemodynamic control during laparoscopic surgery for pheochromocytoma. *Br J Anaesth* 2004; **92**: 512–17.
- 95 Sjoerdsma A. Pheochromocytoma: current concepts of diagnosis and treatment. *Ann Intern Med* 1966; **65**: 1302–26.
- 96 Prys-Roberts C. Pheochromocytoma—recent progress in its management. *Br J Anaesth* 2000; **85**: 44–57.
- 97 Ulchaker JC, Goldfarb DA, Bravo EL, Novick AC. Successful outcomes in pheochromocytoma surgery in the modern era. *J Urol* 1999; **161**: 764–67.
- 98 Prys-Roberts C, Farndon JR. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. *World J Surg* 2002; **26**: 1037–42.
- 99 Kocak S, Aydintug S, Canakci N. Alpha blockade in preoperative preparation of patients with pheochromocytomas. *Int Surg* 2002; **87**: 191–94.

- 100 Lebuffe G, Dosse ED, Tek G, et al. The effect of calcium channel blockers on outcome following the surgical treatment of pheochromocytomas and paragangliomas. *Anaesthesia* 2005; **60**: 439–44.
- 101 Perry RR, Keiser HR, Norton JA, et al. Surgical management of pheochromocytoma with the use of metyrosine. *Ann Surg* 1990; **212**: 621–28.
- 102 Steinsapir J, Carr AA, Prisant LM, Bransome ED Jr. Metyrosine and pheochromocytoma. *Arch Intern Med* 1997; **157**: 901–06.
- 103 Witteles RM, Kaplan EL, Roizen MF. Safe and cost-effective preoperative preparation of patients with pheochromocytoma. *Anesth Analg* 2000; **91**: 302–04.
- 104 Augoustides JG, Abrams M, Berkowitz D, Fraker D. Vasopressin for hemodynamic rescue in catecholamine-resistant vasoplegic shock after resection of massive pheochromocytoma. *Anesthesiology* 2004; **101**: 1022–24.
- 105 Janetschek G, Finkenstedt G, Gasser R, et al. Laparoscopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas. *J Urol* 1998; **160**: 330–4.
- 106 Fernandez-Cruz L, Taura P, Saenz A, Benarroch G, Sabater L. Laparoscopic approach to pheochromocytoma: hemodynamic changes and catecholamine secretion. *World J Surg* 1996; **20**: 762–68.
- 107 Vargas HI, Kavoussi LR, Bartlett DL, et al. Laparoscopic adrenalectomy: a new standard of care. *Urology* 1997; **49**: 673–78.
- 108 Sprung J, O'Hara JF Jr, Gill IS, Abdelmalak B, Sarnaik A, Bravo EL. Anesthetic aspects of laparoscopic and open adrenalectomy for pheochromocytoma. *Urology* 2000; **55**: 339–43.
- 109 Gill IS. The case for laparoscopic adrenalectomy. *J Urol* 2001; **166**: 429–36.
- 110 Walz MK, Peitgen K, Neumann HP, Janssen OE, Philipp T, Mann K. Endoscopic treatment of solitary, bilateral, multiple, and recurrent pheochromocytomas and paragangliomas. *World J Surg* 2002; **26**: 1005–12.
- 111 Jaroszewski DE, Tessier DJ, Schlinkert RT, et al. Laparoscopic adrenalectomy for pheochromocytoma. *Mayo Clin Proc* 2003; **78**: 1501–04.
- 112 Hwang J, Shoaf G, Uchio EM, et al. Laparoscopic management of extra-adrenal pheochromocytoma. *J Urol* 2004; **171**: 72–76.
- 113 Henry JF, Defechereux T, Raffaelli M, Lubrano D, Gramatica L. Complications of laparoscopic adrenalectomy: results of 169 consecutive procedures. *World J Surg* 2000; **24**: 1342–46.
- 114 Cheah WK, Clark OH, Horn JK, Siperstein AE, Duh QY. Laparoscopic adrenalectomy for pheochromocytoma. *World J Surg* 2002; **26**: 1048–51.
- 115 Neumann HP, Reincke M, Bender BU, Elsner R, Janetschek G. Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. *J Clin Endocrinol Metab* 1999; **84**: 2608–10.
- 116 Walther MM, Herring J, Choyke PL, Linehan WM. Laparoscopic partial adrenalectomy in patients with hereditary forms of pheochromocytoma. *J Urol* 2000; **164**: 14–17.
- 117 Baghai M, Thompson GB, Young WF Jr, Grant CS, Michels VV, van Heerden JA. Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: a role for laparoscopic and cortical-sparing surgery. *Arch Surg* 2002; **137**: 682–88.
- 118 Brauckhoff M, Gimm O, Brauckhoff K, Dralle H. Repeat adrenocortical-sparing adrenalectomy for recurrent hereditary pheochromocytoma. *Surg Today* 2004; **34**: 251–55.
- 119 Yip L, Lee JE, Shapiro SE, et al. Surgical management of hereditary pheochromocytoma. *J Am Coll Surg* 2004; **198**: 525–34.
- 120 Walz MK. Extent of adrenalectomy for adrenal neoplasm: cortical sparing (subtotal) versus total adrenalectomy. *Surg Clin North Am* 2004; **84**: 743–53.
- 121 Neumann HP, Bender BU, Reincke M, Eggstein S, Laubenberger J, Kirste G. Adrenal-sparing surgery for phaeochromocytoma. *Br J Surg* 1999; **86**: 94–97.
- 122 Niemann U, Hiller W, Behrend M. 25 years experience of the surgical treatment of phaeochromocytoma. *Eur J Surg* 2002; **168**: 716–19.
- 123 Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. *Hypertension* 1997; **29**: 1133–39.
- 124 Brunt LM, Lairmore TC, Doherty GM, Quasebarth MA, DeBenedetti M, Moley JF. Adrenalectomy for familial pheochromocytoma in the laparoscopic era. *Ann Surg* 2002; **235**: 713–20.
- 125 Lehnert H, Mundschenk J, Hahn K. Malignant pheochromocytoma. *Front Horm Res* 2004; **31**: 155–62.
- 126 Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: current status and initiatives for future progress. *Endocr Relat Cancer* 2004; **11**: 423–36.
- 127 Rao F, Keiser HR, O'Connor DT. Malignant pheochromocytoma: chromaffin granule transmitters and response to treatment. *Hypertension* 2000; **36**: 1045–52.
- 128 Januszewicz W, Wocial B, Januszewicz A, Gryglas P, Prejbisz A. Dopamine and dopa urinary excretion in patients with pheochromocytoma—diagnostic implications. *Blood Press* 2001; **10**: 212–16.
- 129 van der Harst E, de Herder WW, de Krijger RR et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. *Eur J Endocrinol* 2002; **147**: 85–94.
- 130 Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. *Ann Intern Med* 1988; **109**: 267–73.
- 131 Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytoma. *Trends Endocrinol Metab* 2001; **12**: 469–75.
- 132 Sisson JC. Radiopharmaceutical treatment of pheochromocytomas. *Ann N Y Acad Sci* 2002; **970**: 54–60.
- 133 Rose B, Matthay KK, Price D, et al. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. *Cancer* 2003; **98**: 239–48.